|
Potent And-1 Inhibitors that Suppress Tumor Growth and Overcome Platinum Drug Resistance
Ovarian cancer (OC) is one of the leading causes of cancer-related deaths in women. The survival rate of ovarian cancer patients is low largely due to platinum-based chemotherapy resistance and lack of alternative regimens. Recent studies showed that the Acidic nucleoplasmic DNA-binding protein 1 (And-1) activation promotes platinum drug resistance...
Published: 2/18/2025
|
Inventor(s): Wenge Zhu, Yiliang Li, Jing Li
Keywords(s):
Category(s): Technology Classifications > Therapeutics > Small Molecules
|
|
SENP1 Enzymatic Activity Inhibitors for Platinum Resistant Ovarian Cancer
Ovarian cancer is one of the leading causes of cancer-related deaths in women. The survival rate of ovarian cancer patients is low largely due to platinum-based chemotherapy resistance and lack of alternative regimens. A recent study indicated that Janus tyrosine kinase 2 (JAK2), which activates the signal transducers and activators of transcription...
Published: 2/18/2025
|
Inventor(s): Wenge Zhu, Jing Li, Ruiqin Wu, Yiliang Li
Keywords(s):
Category(s): Technology Classifications > Therapeutics > Small Molecules
|
|
And-1 Inhibition by DHS for Cancer Treatment
GW researchers developed DHS (4,4’-trans-dihydroxystilbene) as a new cytotoxic anticancer drug for use alone or in combination with other chemotherapies. Drug toxicity and drug resistance limit the ability of many cytotoxic cancer drugs to effectively treat cancer, a problem which is overcome by DHS. The cancer killing efficacy of DHS is 10-times...
Published: 2/18/2025
|
Inventor(s): Chi-Wei Chen, Zhiyong Han, Wenge Zhu, Yongming Li
Keywords(s):
Category(s): Technology Classifications > Therapeutics > Small Molecules
|
